Reissue Patent
USRE44186E1 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
有权
二丙基稠合吡咯烷基二肽基肽酶IV抑制剂及方法
- Patent Title: Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
- Patent Title (中): 二丙基稠合吡咯烷基二肽基肽酶IV抑制剂及方法
-
Application No.: US13308658Application Date: 2011-12-01
-
Publication No.: USRE44186E1Publication Date: 2013-04-30
- Inventor: Jeffrey A. Robl , Richard B. Sulsky , David J. Augeri , David R. Magnin , Lawrence G. Hamann , David A. Betebenner
- Applicant: Jeffrey A. Robl , Richard B. Sulsky , David J. Augeri , David R. Magnin , Lawrence G. Hamann , David A. Betebenner
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Woodcock Washburn LLP
- Main IPC: C07D209/02
- IPC: C07D209/02 ; A61K31/403
Abstract:
Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Information query
